Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
SCYNEXIS Inc
SCYX | US
0.80
USD0.01
0.95%
SCYX | US
About SCYNEXIS Inc
Sector
Healthcare
Industry
Drug Manufacturers-Specialty & Generic
Earnings date
30/06/2024
As of date
06/03/2026
Close
0.80
Open
0.81
High
0.82
Low
0.73
SCYNEXIS Inc. a biotechnology company develops products for the treatment of fungal infections in the United States. It offers BREXAFEMME for the treatment of vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp an intravenous drug for the treatment of various fungal infections including invasive candidiasis refractory invasive fungal infections invasive aspergillosis VVC and recurrent VVC. It has research collaborations with Merck Sharp & Dohme Corp. Hansoh (Shanghai) Health Technology Co. Ltd. Jiangsu Hansoh Pharmaceutical Group Company Limited and R-Pharm CJSC to develop and commercialize rights for ibrexafungerp. The company was formerly known as SCYNEXIS Chemistry & Automation Inc. and changed its name to SCYNEXIS Inc. in June 2002. SCYNEXIS Inc. was incorporated in 1999 and is headquartered in Jersey City New Jersey.
View LessSCYX | US
Risk
73.4
Sharpe
-0.30
Luna's Score
45/100
Recommendation
Sell
Luna says (SCYX | US)
What's Working
Strength based on increasing price with high volume
High Current Volume and Positive 1-Day Return
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
What's not Working
High Short-term Volatility
High 6-Month Volatility (>65%)
Microcap (<300M USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
10 days
65.7%1 month
73.4%3 months
61.9%6 months
73.7%Returns
Fundamental Ratios
PE
-
Fwd. PE
1.94
Price to book
0.95
Debt to equity
0.26
Debt to assets
0.14
Ent. to EBITDA
0.05
Ent. to rev.
0.44
PEG
-
Other Fundamentals
EBITDA
-51.34M
MarketCap
30.29M
MarketCap(USD)
30.29M
Div. yield
-
Op. margin
-1.26K
Erngs. growth
-
Rev. growth
-99.40
Ret. on equity
-46.12
Short ratio
6.51
Short perc.
3.51
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bearish (SMA6M < SMA12M)
SMAs: Stock Price Trends
Range10D
0.14
Range1M
0.16
Range3M
0.29
Volumes: Market Activity
Rel. volume
2.61
Price X volume
779.36K
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 0.05 | 24.85 | Cheaper |
| Ent. to Revenue | 0.44 | 361.91 | Cheaper |
| PE Ratio | - | 30.05 | - |
| Price to Book | 0.95 | 13.15 | Cheaper |
| Dividend Yield | - | 2.94 | - |
| Std. Deviation (3M) | 61.89 | 65.24 | Par |
| Debt to Equity | 0.26 | -1.88 | Expensive |
| Debt to Assets | 0.14 | 0.48 | Cheaper |
| Market Cap | 30.29M | 3.71B | Emerging |
